{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-4MLDVTY5/b47f6306-51de-461c-9158-2bb7c9087647/HTML","dcterms:extent":"30 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-4MLDVTY5/d52c8599-dc13-48bd-bb90-f43ab76c3c55/PDF","dcterms:extent":"128 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-4MLDVTY5/fdc8e246-370a-4f94-9594-3bbc47738b11/TEXT","dcterms:extent":"28 KB"}],"edm:TimeSpan":{"@rdf:about":"1929-2026","edm:begin":{"@xml:lang":"en","#text":"1929"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:DOC-4MLDVTY5","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp"},{"@xml:lang":"sl","#text":"Zdravniški vestnik"}],"dcterms:issued":"2003","dc:creator":["Korošec, Bojan","Lainščak, Mitja"],"dc:format":[{"@xml:lang":"sl","#text":"številka:5"},{"@xml:lang":"sl","#text":"letnik:72"},{"@xml:lang":"sl","#text":"str. 265-269"}],"dc:identifier":["ISSN:1318-0347","COBISSID:16298713","URN:URN:NBN:SI:doc-4MLDVTY5"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"dc:subject":[{"@xml:lang":"en","#text":"Adrenergic Beta-Antagonists"},{"@xml:lang":"sl","#text":"Adrenergični beta-antagonisti"},{"@xml:lang":"sl","#text":"Ambulantna oskrba"},{"@xml:lang":"en","#text":"Ambulatory Care"},{"@xml:lang":"en","#text":"Angiotensin-Converting Enzyme Inhibitors"},{"@xml:lang":"sl","#text":"Angiotenzin-pretvorba, encimski inhibitorji"},{"@xml:lang":"en","#text":"drug"},{"@xml:lang":"en","#text":"Drug Therapy"},{"@xml:lang":"en","#text":"Heart Failure, Congestive"},{"@xml:lang":"sl","#text":"Hospitalizacija"},{"@xml:lang":"en","#text":"Hospitalization"},{"@xml:lang":"sl","#text":"kardiologija"},{"@xml:lang":"sl","#text":"Kvaliteta življenja"},{"@xml:lang":"en","#text":"Prognosis"},{"@xml:lang":"sl","#text":"Prognoza"},{"@xml:lang":"en","#text":"Quality Of Life"},{"@xml:lang":"sl","#text":"Srce, odpoved kongestivna"},{"@xml:lang":"sl","#text":"srčno popuščanje"},{"@xml:lang":"en","#text":"therapy"},{"@xml:lang":"sl","#text":"zdravila"},{"@xml:lang":"sl","#text":"zdravljenje"}],"dcterms:temporal":{"@rdf:resource":"1929-2026"},"dc:title":{"@xml:lang":"sl","#text":"Uporaba zdravil in kakovost življenja bolnikov v ambulanti za srčno popuščanje| Use of drugs and patient's quality of life in heart failure clinic|"},"dc:description":[{"@xml:lang":"sl","#text":"Background. Heart failure is associated with poor quality of life and frequenthospitalizations. Implementation of the clinical trials results, especially prescription of adequate daily doses, is regarded as insufficient. In Slovenia there is no data on quality of life in patients treated in heart failure clinic. Aim. This study assessed the effects of heart failure clinic on patients pharmacological treatment, number of hospitalisations and quality of life. Methods. Patients with established heart failure were enrolled on a basis of the European Society of Cardiology guadelines. Results. During seven months 48 patients (28 men and 20 women), aged 68.4 +- 11.9 years were included. Half of the patients referred after heart failure hospitalisation. After mean of 3.8 +- 1.5 visits in mean time of 2.9 +- 2.6 months more patients received angiotenzin converting enzyme inhibitors and beta adrenergicblockers (90 vs. 100% p < 0.05 and 42% vs. 88%, p < 0.001, respectively). There was also an increase in mean daily dose of both drugs: from 60% to 86% for angiotenzin converting enzyme inhibitors and from 26% to 44% for beta adrenergic blockers (p < 0.001 for both). Hospital admissions were reduced by 79%. Quadity of life, health, MLHFQ result and NYHA class all significantly improved (p < 0.001)"},{"@xml:lang":"sl","#text":"Izhodišča. Srčno popuščanje je povezano s slabo kakovostjo življenja bolnikov in pogostimi hospitalizacijami. Udejanjanje rezultatov kliničnih raziskav v klinični praksi, predvsem glede ciljnih odmerkov zdravil, je nezadostno. V Sloveniji nimamo podatkov o vplivu ambulantne obravnave na kakovost življenja bolnikov s srčnim popuščanjem. Namen. Ugotoviti vpliv ambulantne obravnave bolnikov s srčnim popuščanjem na farmakološko zdravljenje, število hospitalizacij in kakovost njihovega življenja. Metode. V prospektivni raziskavi smo v register vključili bolnike, pri katerih smo glede na smernice Evropskega kardiološkega združenja ugotovili srčno popuščanje. Rezultati. V obdobju sedmih mesecev smo vključili 48 bolnikov (28 moških in 20 žensk), ki so bili v povprečju stari 68,4 +- 11,9 leta. Polovica bolnikov je bila v ambulanto napotena po hospitalizaciji zaradi srčnega popuščanja. Bolniki so bili povpreč no opazovani 2,9 +- 2,6 meseca in v tem času pregdedani povprečno3,8 +- 1,5-krat. V tem času smo značilno povečali deleže bolnikov, kiso prejemali zaviralce angiotenzinske konvertaze (90% na 100% p < 0,05) in zaviralce betaadrenergičnih receptorjev (42% na 88%, p <0,001). Povprečni dnevni odmerek zaviralcev angiotenzinske konvertaze smo uspeli povišati od 60%na 86% (p < 0,001), zaviralcev betaadrenergičnih receptarjev pa od 26% na 44% (p < 0, 001). Število hospitalizacij pri bolnikih po hospitalizaciji je bilo manjše za 79%. Ob zadnjem pregledu smo ugotavljali značilno boljšo kakovost življenja, zdravje, rezultat Minesotta vprašalnika o srčnem popuščanju in razreda po klasifikaciji NYHA (p < 0,001 za vse)"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:DOC-4MLDVTY5","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:DOC-4MLDVTY5"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:DOC-4MLDVTY5/d52c8599-dc13-48bd-bb90-f43ab76c3c55/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:DOC-4MLDVTY5/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:DOC-4MLDVTY5"}}}}